张祥宏. 食管胃交界腺癌诊断治疗的有关问题[J]. 中国肿瘤临床, 2008, 35(21): 1201-1205.
引用本文: 张祥宏. 食管胃交界腺癌诊断治疗的有关问题[J]. 中国肿瘤临床, 2008, 35(21): 1201-1205.
ZHANG Xiang-hong. Current Topics in the Diagnosis and Treatment of Adenocarcinoma of the Esophagogastric Junction[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(21): 1201-1205.
Citation: ZHANG Xiang-hong. Current Topics in the Diagnosis and Treatment of Adenocarcinoma of the Esophagogastric Junction[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(21): 1201-1205.

食管胃交界腺癌诊断治疗的有关问题

Current Topics in the Diagnosis and Treatment of Adenocarcinoma of the Esophagogastric Junction

  • 摘要: 食管胃交界腺癌(Adenocarcinoma of Esophagogastric Junction,AEG)是指发生于食管胃交界区域的腺癌,包括食管远端腺癌和胃近端腺癌。在过去的几十年中欧美国家人群远端胃癌发生率明显下降而AEG的发生率显著增高,多数学者认为AEG是一独特的临床类型,预后较差。由于AEG发生于食管胃交界区域,分类和治疗一直比较混乱,应用比较广泛有Siewert等的解剖学分类,将AEG分为三型,Ⅰ型为远端食管腺癌,主要来源于Barrett食管;Ⅲ型为贲门下癌,而Ⅱ型肿瘤中心位于食管胃交界近侧1cm远侧2cm之间,为真正的贲门癌。WHO也提出了AEAGE最G主的要分的类治。疗目方前法,在,影AE响G手的术TN切M除分预期后、的食因管素胃包交括界肿的瘤确分定期及、贲切门缘的状定态义、淋等巴方结面受还累存情在况不等少。争对议肿。瘤手体术积切较除是大的患者应当选择多种新辅助治疗(常用药物为顺铂和5-FU)。对肿瘤不能完全切除的患者应采取包括放疗、化疗及姑息方法在内的综合治疗。迄今为止,国内肿瘤界对发生于食管胃交界区域的腺癌一般统称贲门癌,初步研究发现我国部分地区贲门癌的发生近十几年来呈明显增高趋势,但有关AEG的研究还非常少。因此,建议国内肿瘤界同仁高度重视AEG的研究,开展大规模的协作,对近几十年来我国胃癌发生部位的变化情况、准确的AEG发生情况、国关人键AE词G与食西管方胃人交群界的腺差癌异、A分E类G的生诊物断学行治为疗等开展系统研究工作,为AEG的合理防治奠定科学基础。

     

    Abstract: Adenocarcinoma of the esophagogastric junction (AEG) is an adenocarcinoma that arises in the vicinityof the esophagogastric junction, including tumors in the distal esophagus and in the proximal stomach. Overthe past few decades, Western European and North American countries have witnessed a rapid increase inthe incidence of AEG. AEG has historically been considered a unique clinical entity with a poor prognosis.There has been longstanding confusion in the classification and treatment of AEG. The most widely adoptedclassification system of AEG is Siewert' s topographic classification. In this classification, type Ⅰ is distalesophageal adenocarcinoma and is believed to arise from Barrett' s esophagus, while type Ⅲ is adenocarci-noma of the gastric subcardia. Type Ⅱ adenocarcinoma is located between 1 cm proximal and 2 cm distal ofthe EGJ and is defined as a true carcinoma of the gastric cardia. WHO AEG classification is also used. Thereis still some controversy on the proper staging of AEG, especially that of N staging. The defining landmarks ofthe esophagogastric junction and the definition of the cardia remain controversial. Surgical resection is themain therapy for patients with no evidence of distant metastases. The prognostic factors for surgical treatmentinclude tumor stage, esophageal resection margin and lymph node involvement. Neoadjuvant therapy shouldbe used for AEG patients with larger tumors. Multimodality treatment including radiotherapy, chemotherapyand palliative surgery can be administered for advanced AEG patients. Almost all of the adenocarcinomasarising in the area of the esophagogastric junction were generally called carcinoma of the gastric cardia in Chi-na. Preliminary studies showed that the incidence of carcinoma of the gastric cardia has increased in the pastfew decades in some rural areas of China, but there are few formal studies on AEG. We suggest that oncolo-gists pay more attention to the study of AEG, including the epidemiological changes affecting AEG during thepast several decades in China, the putative similarity and differences in the etiology and clinical features ofAEG between Chinese and Western people, and the biological features of AEG.

     

/

返回文章
返回